Results 201 to 210 of about 208,254 (303)

Novel targeted therapies for immunoglobulin light chain amyloidosis: latest updates from the 2024 ASH annual meeting. [PDF]

J Hematol Oncol
Bu Q, Zhu HH, Chen W.
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

A mouse model of cardiac immunoglobulin light chain amyloidosis reveals insights into tissue accumulation and toxicity of amyloid fibrils. [PDF]

Nat Commun
Martinez-Rivas G, Ayala MV, Bender S, Codo GR, Swiderska WK, Lampis A, Pedroza L, Merdanovic M, Sicard P, Pinault E, Richard L, Lavatelli F, Giorgetti S, Canetti D, Rinsant A, Kaaki S, Ory C, Oblet C, Pollet J, Naser E, Carpinteiro A, Roussel M, Javaugue V, Jaccard A, Bonaud A, Delpy L, Ehrmann M, Bridoux F, Sirac C.   +28 more
europepmc   +1 more source

Systemic Immunoglobulin Light Chain Amyloidosis Involving the Large Intestine. [PDF]

ACG Case Rep J, 2021
Swaminathan R, Igbinedion S, Pandit S.
europepmc   +1 more source

Development of Raman Spectroscopy and Machine Learning Methods for Protein Aggregate Quantification: Application to BSA in Chromatographic Processes

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Protein aggregation poses a significant risk to biopharmaceutical product quality, as even minor amounts of oligomeric species can compromise efficacy and safety. Rapid and reliable detection of protein aggregates thus remains a major challenge in biopharmaceutical manufacturing.
Jakob Heyer‐Müller, Robin Schiemer, Lars Robbel, Michael Schmitt, Jürgen Hubbuch   +4 more
wiley   +1 more source

Multimodal Chromatography in the Downstream Processing of mAb‐Based Products: Mechanisms, Strategies, and Applications

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Multimodal chromatography has emerged as a powerful tool for the purification of monoclonal antibodies (mAbs) and their derivatives—including antibody fragments (Fabs), Fc‐fusions, bispecific (BsAb), and antibody–drug conjugates (ADCs)—offering enhanced selectivity through the integration of ionic, hydrophobic, hydrogen‐bonding, and π–π ...
Amin Javidanbardan, Marco P․ C․ Marques, Ana M. Azevedo, Daniel G. Bracewell, Stephen Goldrick   +4 more
wiley   +1 more source

Clonal hematopoiesis of indeterminate potential in patients with immunoglobulin light-chain AL amyloidosis. [PDF]

Blood Adv
Lopedote P, Evans B, Marchetti A, Chen T, Moscvin M, Boullt S, Bolli N, Bianchi G.   +7 more
europepmc   +1 more source

Engineered Bacterial Ligand From Streptococcus pneumoniae on Macroporous Resins for Selective Affinity Capture of Secretory IgA

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Secretory immunoglobulin A (sIgA) is a promising emerging biopharmaceutical candidate, but it currently lacks a standardized platform for purification. To address this, a novel affinity chromatography resin was developed by immobilizing protein variants of the Streptococcus pneumoniae surface protein, SpsA, as an affinity ligand.
David Scheich, Andres Männik, Oliver Meikar, Joan Teyra, Laura Kibena, Sebastiaan Eeltink, Rainer Hahn, Alois Jungbauer, Nico Lingg   +8 more
wiley   +1 more source

The clinical trials landscape in immunoglobulin light chain amyloidosis: a systematic review. [PDF]

Blood Adv
Ramachandran R, Shah D, Luo C, Shah V, Cliff ERS, Sanchorawala V, Lentzsch S, Chakraborty R.   +7 more
europepmc   +1 more source

Elementary immunology [PDF]

, 2017
Gogolák, Péter, Koncz, Gábor
core